

**AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs**

**Decision Making Support Tool**

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference: 0070		APCBSSE/0070
Drug name and formulations:		Melatonin modified-release tablets (Circadin®)
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Other hypnotics may be indicated in falls. Little evidence presented beyond this. Third most common side effect of melatonin is listed as dizziness.
Clinical effectiveness	<i>Established licensed product</i>	Little evidence presented
Strength of evidence		Little evidence presented
Cost effectiveness or resource impact	£	Significantly more expensive than benzodiazepines and Z drugs
Place of therapy relative to available treatments	<i>1/2<sup>nd</sup> tier</i>	Not clarified
National guidance and priorities	<i>NICE, MTRAC</i>	MTRAC, SMC did not support
Local health priorities	<i>CCG views</i>	Concerns about evidence presented, the cohort of patients not clearly defined. Although the management of frailty and reduction of falls in elderly/frail is a local priority, there was little evidence presented that this would help in this regard.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

**Decision Summary**

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	Patient population not clearly defined
Formulary status (RAG) and rationale	To remain as RED status
Implementation requirements:	
Implementation monitoring:	